{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:23:53Z","timestamp":1780082633118,"version":"3.54.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The population-based prevalence of psoriatic arthritis (PsA) is still unclear and not well described globally. The aim of this study was to conduct a population-based prevalence projection and provide long-term future estimations of PsA patients in Germany until 2050, using the illness\u2013death model and based on historical data. We analyzed the national statutory health insurance data of 65 million population in the German Institute for Medical Documentation and Information between January 2009 and December 2012. We constructed an estimation of the PsA burden among the German population using the relevant epidemiological parameters to project the numbers of patients with PsA in Germany until 2050 under five possible scenarios by varying the incidence and mortality. The overall conservatively estimated prevalence of PsA in Germany in 2019 was 0.31% (95% CI 0.28\u20130.36%). Women contribute a higher prevalence than men in all five scenarios. In the assumed scenarios with increased incidence, the prevalence of PsA at 60\u00a0years of age could rise from 1% in 2019 to more than 3% in 2050 for both genders, with the increase particularly pronounced for women, reaching around 3.5%. However, in the assumed scenarios with decreasing incidence, the prevalence curve may flatten and begin a decreasing trend from 2035 to 2050 for both genders, achieving a prevalence of less than 1% in 2050. Our research is to generate assumed population-based data on PsA in Germany that can serve as a reference for public health stakeholders to prepare an optional intervention. We would expect worryingly high numbers in the coming decades if preventive strategies are not implemented. In the long term, it will be necessary to implement preventive strategies to identify predictors and treat psoriasis symptoms early in order to delay or even prevent the transition of psoriasis to PsA.<\/jats:p>","DOI":"10.1007\/s00296-023-05422-2","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T15:05:13Z","timestamp":1692457513000},"page":"2037-2047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A population-based projection of psoriatic arthritis in Germany until 2050: analysis of national statutory health insurance data of 65 million German population"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-9702","authenticated-orcid":false,"given":"Jiancong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-5167","authenticated-orcid":false,"given":"Sabrina","family":"Tulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-4475","authenticated-orcid":false,"given":"Stephanie","family":"Knippschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-0035","authenticated-orcid":false,"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7408-9333","authenticated-orcid":false,"given":"J\u00f6rg H. W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-6592","authenticated-orcid":false,"given":"Ralph","family":"Brinks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-6207","authenticated-orcid":false,"given":"Philipp","family":"Sewerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"issue":"10","key":"5422_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"5422_CR2","unstructured":"National Health Service (2023) Psoriatic arthritis. https:\/\/www.nhs.uk\/conditions\/psoriatic-arthritis\/#:~:text=Psoriatic%20arthritis%20is%20a%20type,that%20can%20get%20progressively%20worse. Accessed 28 July 2023"},{"issue":"10136","key":"5422_CR3","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","volume":"391","author":"F Van den Bosch","year":"2018","unstructured":"Van den Bosch F, Coates L (2018) Clinical management of psoriatic arthritis. Lancet 391(10136):2285\u20132294. https:\/\/doi.org\/10.1016\/S0140-6736(18)30949-8","journal-title":"Lancet"},{"issue":"1","key":"5422_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/acr.24412","volume":"73","author":"G Haugeberg","year":"2021","unstructured":"Haugeberg G, Lund Nilsen TI, Kavanaugh A et al (2021) Physical and psychosocial burden of psoriatic arthritis: longitudinal data from a population-based study in Norway. Arthritis Care Res (Hoboken) 73(1):138\u2013145. https:\/\/doi.org\/10.1002\/acr.24412","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"5422_CR5","doi-asserted-by":"publisher","first-page":"rkaa033","DOI":"10.1093\/rap\/rkaa033","volume":"4","author":"J Rech","year":"2020","unstructured":"Rech J, Sticherling M, Stoessel D et al (2020) Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. Rheumatol Adv Pract 4(2):rkaa033. https:\/\/doi.org\/10.1093\/rap\/rkaa033","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"5422_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00296-019-04319-3","volume":"39","author":"M Bedaiwi","year":"2019","unstructured":"Bedaiwi M, Al-Homood IA, El-Garf A et al (2019) Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East. Rheumatol Int 39(8):1321\u20131329. https:\/\/doi.org\/10.1007\/s00296-019-04319-3","journal-title":"Rheumatol Int"},{"issue":"1","key":"5422_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti L, Franchi M, Marchesoni A et al (2018) Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48(1):28\u201334. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.003","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"5422_CR8","doi-asserted-by":"publisher","first-page":"adv00566","DOI":"10.2340\/00015555-3879","volume":"101","author":"R Maximilian","year":"2021","unstructured":"Maximilian R, Garbe C, Petersen J et al (2021) Epidemiology, comorbidity and risk factors for psoriatic arthritis: a health insurance claims database analysis. Acta Derm Venereol 101(10):adv00566. https:\/\/doi.org\/10.2340\/00015555-3879","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"5422_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/annrheumdis-2013-203862","volume":"74","author":"M Hoff","year":"2015","unstructured":"Hoff M, Gulati AM, Romundstad PR et al (2015) Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Tr\u00f8ndelag health study (HUNT). Ann Rheum Dis 74(1):60\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203862","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5422_CR10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/art.41741","volume":"73","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Crowson CS, Bekele D et al (2021) The epidemiology of psoriatic arthritis over five decades: a population-based study. Arthritis Rheumatol 73(10):1878\u20131885. https:\/\/doi.org\/10.1002\/art.41741","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"5422_CR11","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2016-210963","volume":"76","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Kristensen LE, Thyssen JP et al (2017) Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann Rheum Dis 76(9):1591\u20131597. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210963","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5422_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","volume":"270","author":"O Ahlehoff","year":"2011","unstructured":"Ahlehoff O, Gislason GH, Charlot M et al (2011) Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270(2):147\u2013157. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02310.x","journal-title":"J Intern Med"},{"issue":"8","key":"5422_CR13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/acr.23743","volume":"71","author":"L Eder","year":"2019","unstructured":"Eder L, Widdifield J, Rosen CF et al (2019) Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken) 71(8):1084\u20131091. https:\/\/doi.org\/10.1002\/acr.23743","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"5422_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/dme.13902","volume":"36","author":"T T\u00f6nnies","year":"2019","unstructured":"T\u00f6nnies T, R\u00f6ckl S, Hoyer A et al (2019) Projected number of people with diagnosed Type 2 diabetes in Germany in 2040. Diabet Med 36(10):1217\u20131225. https:\/\/doi.org\/10.1111\/dme.13902","journal-title":"Diabet Med"},{"key":"5422_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tpb.2013.11.006","volume":"92","author":"R Brinks","year":"2014","unstructured":"Brinks R, Landwehr S (2014) Age- and time-dependent model of the prevalence of non-communicable diseases and application to dementia in Germany. Theor Popul Biol 92:62\u201368. https:\/\/doi.org\/10.1016\/j.tpb.2013.11.006","journal-title":"Theor Popul Biol"},{"issue":"10","key":"5422_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/s2213-8587(22)00218-2","volume":"10","author":"GA Gregory","year":"2022","unstructured":"Gregory GA, Robinson TIG, Linklater SE et al (2022) Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol 10(10):741\u2013760. https:\/\/doi.org\/10.1016\/s2213-8587(22)00218-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"5422_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40271-017-0221-4","volume":"10","author":"E Dures","year":"2017","unstructured":"Dures E, Hewlett S, Lord J et al (2017) Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study. Patient 10(4):455\u2013462. https:\/\/doi.org\/10.1007\/s40271-017-0221-4","journal-title":"Patient"},{"key":"5422_CR18","unstructured":"German Institute for Medical Documentation and Information (DIMDI) (2023) https:\/\/www.dimdi.de\/dynamic\/de\/startseite\/. Accessed 28 July 2023"},{"key":"5422_CR19","unstructured":"German Institute for Medical Documentation and Information (DIMDI) (2023) Psoriatic arthritis diagnoses according to the 10th edition of the International Statistical Classification of Diseases and Related Health Problems (WHO Version 1.3). https:\/\/www.dimdi.de\/static\/de\/klassifikationen\/icd\/icd-10-who\/kode-suche\/htmlamtl\/index.htm?gm05.htm+. Accessed 28 July 2023"},{"key":"5422_CR20","unstructured":"Association of Substitute Funds (Verband der Ersatzkassen). Healthcare Data: Insured. https:\/\/www.vdek.com\/presse\/daten\/b_versicherte.html. Accessed 28 July 2023"},{"key":"5422_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001975","author":"M Deike","year":"2021","unstructured":"Deike M, Brinks R, Meller S et al (2021) Risk of psoriatic arthritis depending on age: analysis of data from 65 million people on statutory insurance in Germany. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001975","journal-title":"RMD Open"},{"key":"5422_CR22","unstructured":"Federal Statistical Office of Germany (2023) The 14th Coordinated population projection for Germany. https:\/\/service.destatis.de\/bevoelkerungspyramide\/index.html#!l=en. Accessed 28 July 2023"},{"issue":"4","key":"5422_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/imammb\/dqu024","volume":"32","author":"R Brinks","year":"2015","unstructured":"Brinks R, Landwehr S (2015) A new relation between prevalence and incidence of a chronic disease. Math Med Biol 32(4):425\u2013435. https:\/\/doi.org\/10.1093\/imammb\/dqu024","journal-title":"Math Med Biol"},{"key":"5422_CR24","unstructured":"Berman HB. Interaction Effects in Regression. https:\/\/stattrek.com\/multiple-regression\/interaction. Accessed 28 July 2023"},{"key":"5422_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-12-812253-2.00012-1","volume-title":"Computational nuclear engineering and radiological science using python","author":"RG McClarren","year":"2018","unstructured":"McClarren RG (2018) Chapter 10 - interpolation. In: McClarren RG (ed) Computational nuclear engineering and radiological science using python. Academic Press, pp 173\u2013192"},{"issue":"3418","key":"5422_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1126\/science.132.3418.14","volume":"132","author":"BL Strehler","year":"1960","unstructured":"Strehler BL, Mildvan AS (1960) General theory of mortality and aging. Science 132(3418):14\u201321","journal-title":"Science"},{"issue":"4","key":"5422_CR27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.4143\/crt.2021.902","volume":"54","author":"KJ Chae","year":"2022","unstructured":"Chae KJ, Choi H, Jeong WG et al (2022) The value of the illness-death model for predicting outcomes in patients with non-small cell lung cancer. Cancer Res Treat 54(4):996\u20131004. https:\/\/doi.org\/10.4143\/crt.2021.902","journal-title":"Cancer Res Treat"},{"issue":"3","key":"5422_CR28","doi-asserted-by":"publisher","first-page":"e0264739","DOI":"10.1371\/journal.pone.0264739","volume":"17","author":"D Voeltz","year":"2022","unstructured":"Voeltz D, T\u00f6nnies T, Brinks R et al (2022) Future prevalence of type 2 diabetes-A comparative analysis of chronic disease projection methods. PLoS\u00a0One 17(3):e0264739. https:\/\/doi.org\/10.1371\/journal.pone.0264739","journal-title":"PLoS\u00a0One"},{"issue":"11","key":"5422_CR29","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2019-215313","volume":"78","author":"J Guldberg-M\u00f8ller","year":"2019","unstructured":"Guldberg-M\u00f8ller J, Cordtz RL, Kristensen LE et al (2019) Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis 78(11):1517\u20131523. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215313","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5422_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.15021","volume":"176","author":"DA Springate","year":"2017","unstructured":"Springate DA, Parisi R, Kontopantelis E et al (2017) Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol 176(3):650\u2013658. https:\/\/doi.org\/10.1111\/bjd.15021","journal-title":"Br J Dermatol"},{"key":"5422_CR31","doi-asserted-by":"publisher","first-page":"adv00807","DOI":"10.2340\/actadv.v102.1962","volume":"102","author":"IYK Iskandar","year":"2022","unstructured":"Iskandar IYK, Chen TC, Chen LC et al (2022) Incidence, prevalence, and mortality of people with psoriasis and psoriatic arthritis in taiwan: a nationwide cohort study. Acta Derm Venereol 102:adv00807. https:\/\/doi.org\/10.2340\/actadv.v102.1962","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"5422_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5422_CR33","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","volume":"71","author":"TJ Love","year":"2012","unstructured":"Love TJ, Zhu Y, Zhang Y et al (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71(8):1273\u20131277. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201299","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5422_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjd.18227","volume":"182","author":"A Green","year":"2020","unstructured":"Green A, Shaddick G, Charlton R et al (2020) Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol 182(3):714\u2013720. https:\/\/doi.org\/10.1111\/bjd.18227","journal-title":"Br J Dermatol"},{"issue":"5","key":"5422_CR35","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/acr.24820","volume":"75","author":"H Chaudhary","year":"2023","unstructured":"Chaudhary H, Bohra N, Syed K et al (2023) All-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 75(5):1052\u20131065. https:\/\/doi.org\/10.1002\/acr.24820","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"5422_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.18553\/jmcp.2018.24.7.654","volume":"24","author":"S Lee","year":"2018","unstructured":"Lee S, Xie L, Wang Y et al (2018) Evaluating the effect of treatment persistence on the economic burden of moderate to severe psoriasis and\/or psoriatic arthritis patients in the U.S. department of defense population. J Manag Care Spec Pharm 24(7):654\u2013663. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.654","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"5422_CR37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40744-022-00435-y","volume":"9","author":"P Richette","year":"2022","unstructured":"Richette P, Coates LC, Azevedo VF et al (2022) Patient Perception of medical care for psoriatic arthritis in north America and Europe: results from a global patient survey. Rheumatol Ther 9(3):823\u2013838. https:\/\/doi.org\/10.1007\/s40744-022-00435-y","journal-title":"Rheumatol Ther"},{"issue":"5","key":"5422_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.semarthrit.2021.08.006","volume":"51","author":"AM Kerola","year":"2021","unstructured":"Kerola AM, Sexton J, Wibetoe G et al (2021) Incidence, sociodemographic factors and treatment penetration of rheumatoid arthritis and psoriatic arthritis in Norway. Semin Arthritis Rheum 51(5):1081\u20131088. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.08.006","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"5422_CR39","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A et al (2015) The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med 12(10):e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885","journal-title":"PLoS Med"},{"issue":"4","key":"5422_CR40","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/03009740903544212","volume":"39","author":"P Hanova","year":"2010","unstructured":"Hanova P, Pavelka K, Holcatova I et al (2010) Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic. Scand J Rheumatol 39(4):310\u2013317. https:\/\/doi.org\/10.3109\/03009740903544212","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"5422_CR41","doi-asserted-by":"publisher","first-page":"e0234556","DOI":"10.1371\/journal.pone.0234556","volume":"15","author":"A Romero P\u00e9rez","year":"2020","unstructured":"Romero P\u00e9rez A, Queiro R, Seoane-Mato D et al (2020) Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. PLoS\u00a0One 15(6):e0234556. https:\/\/doi.org\/10.1371\/journal.pone.0234556","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"5422_CR42","first-page":"819","volume":"23","author":"F Salaffi","year":"2005","unstructured":"Salaffi F, De Angelis R, Grassi W (2005) Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 23(6):819\u2013828","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"5422_CR43","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","volume":"35","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Deshpande GA, Fukuoka K et al (2021) Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol 35(2):101670. https:\/\/doi.org\/10.1016\/j.berh.2021.101670","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"5422_CR44","unstructured":"World Health Organization (2016) Global report on psoriasis. https:\/\/apps.who.int\/iris\/handle\/10665\/204417. Accessed 28 July 2023"},{"issue":"3","key":"5422_CR45","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/joim.13311","volume":"290","author":"AB Tinggaard","year":"2021","unstructured":"Tinggaard AB, Hjuler KF, Andersen IT et al (2021) Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi-centre cohort study. J Intern Med 290(3):693\u2013703. https:\/\/doi.org\/10.1111\/joim.13311","journal-title":"J Intern Med"},{"issue":"4","key":"5422_CR46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/acr.23518","volume":"70","author":"DF Battafarano","year":"2018","unstructured":"Battafarano DF, Ditmyer M, Bolster MB et al (2018) 2015 American college of rheumatology workforce study: supply and demand projections of adult rheumatology workforce, 2015\u20132030. Arthritis Care Res (Hoboken) 70(4):617\u2013626. https:\/\/doi.org\/10.1002\/acr.23518","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"5422_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5114\/ada.2020.94835","volume":"37","author":"A Kisielnicka","year":"2020","unstructured":"Kisielnicka A, Szczerkowska-Dobosz A, Nowicki RJ (2020) The influence of body weight of patients with chronic plaque psoriasis on biological treatment response. Postepy Dermatol Alergol 37(2):168\u2013173. https:\/\/doi.org\/10.5114\/ada.2020.94835","journal-title":"Postepy Dermatol Alergol"},{"issue":"2","key":"5422_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11154-017-9411-6","volume":"18","author":"L Barrea","year":"2017","unstructured":"Barrea L, Savanelli MC, Di Somma C et al (2017) Vitamin D and its role in psoriasis: an overview of the dermatologist and nutritionist. Rev Endocr Metab Disord 18(2):195\u2013205. https:\/\/doi.org\/10.1007\/s11154-017-9411-6","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"5422_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF et al (2019) Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol 15(3):153\u2013166. https:\/\/doi.org\/10.1038\/s41584-019-0175-0","journal-title":"Nat Rev Rheumatol"},{"key":"5422_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-022-01302-5","author":"K Albrecht","year":"2023","unstructured":"Albrecht K, Binder S, Minden K et al (2023) Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. Z Rheumatol. https:\/\/doi.org\/10.1007\/s00393-022-01302-5","journal-title":"Z Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05422-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T06:07:12Z","timestamp":1694412432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05422-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["5422"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05422-2","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no conflict of interest relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the datasets in the current study were in an aggregated data format; written informed consent and ethical approval were therefore not required. This study has been approved and supported by the Hiller Research Center, University Hospital D\u00fcsseldorf, Medical Faculty of Heinrich Heine University. All authors had full access to the study dataset and take responsibility for data protection protocols.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable\u2014our manuscript does not contain data from any individual person.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}